Public advisory - Dianeal PD4 2.5% Dextrose and Physioneal 40 2.27% Glucose peritoneal dialysis solutions recalled due to risk of leakage at connection site
What to do: Immediately check your stock to see if your product is affected. If you have an affected product, do not use it and immediately speak to your health care provider to obtain a replacement. Consult a health care professional if you have used the affected product and you have health concerns.
Affected products
Product
DIN
Lot
Expiry
Dianeal PD4 2.5% Dextrose 3,000 mL
00865109
W4C09T0
03/31/2026
Dianeal PD4 2.5% Dextrose 5,000 mL
00865109
W4B26T4
W4B29T1
W4C07T1
W4C18T2
02/28/2026
02/28/2026
03/31/2026
03/31/2026
Physioneal 40 2.27% Glucose 2,500 mL
02247722
W4B26T2
02/28/2025
Issue
Vantive ULC (a subsidiary of Baxter Corporation) is recalling certain lots of Dianeal and Physioneal peritoneal dialysis solutions because of possible leakage at the connection site . The affected lots were distributed in Canada between March 6, 2024, and May 29, 2024.
Dianeal and Physioneal are sterile peritoneal dialysis solutions used in hospitals and home settings to treat patients whose kidneys are not working properly.
Products with leakage at the connection site may become contaminated, exposing patients to microbial contamination and an increased risk of peritonitis. Peritonitis is when the thin layer of tissue inside the abdomen, called the peritoneum, becomes inflamed. Symptoms of peritonitis include fever and chills, belly pain or tenderness, feeling bloated, upset stomach and vomiting, loss of appetite, diarrhea or constipation, extreme fatigue and confusion. Peritonitis can result in death.
Health Canada is monitoring the company's recall, and its implementation of any necessary corrective and preventative actions to prevent this issue from reoccurring. The Department will inform the public if any new health risks are identified.
What you should do
Immediately check your stock to see if your product is affected. If you have an affected product, do not use it, and immediately speak to your health care provider to obtain a replacement.
Consult a health care professional if you have used the affected product and you have health concerns.
Contact Baxter Corporation toll-free at 1-888-719-9955 if you have questions about the recall.
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...
YOUR LEGAL RIGHTS MAY BE AFFECTED
There is a proposed settlement in a class-action lawsuit filed against Pfizer Inc., Pfizer Ireland Pharmaceuticals, Warner-Lambert Company, and Warner-Lambert Company LLC (collectively, "Pfizer") and Ranbaxy Inc.,...
In a landmark event signaling its ambitious foray into the biopharmaceutical sector, LOTTE BIOLOGICS, under the leadership of CEO Richard W. Lee, held a groundbreaking ceremony for its inaugural plant at the Songdo Bio Campus in Incheon International...
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies for hematological malignancies, announced today that on July 2, 2024, in relation to...
Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal...